Design Therapeutics
Corey Driscoll has been working in the scientific field since 2015. Corey started at Toxikon Corporation as a Research Associate I, In Vitro and then moved to a Research Associate, In Vitro role. In 2017, they joined Novartis Institutes for BioMedical Research (NIBR) as a Scientific Associate (Contract), then moved to a Scientific Associate II role, and finally a Senior Scientist I role. Most recently, in 2021, they joined Design Therapeutics as an Associate Scientist.
Corey Driscoll graduated from the University of Massachusetts Lowell in 2015 with a Bachelor of Science in Biology, General.
This person is not in any offices
Design Therapeutics
1 followers
Design Therapeutics is pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras (GeneTACs™), designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.